Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam J Mead

Showing results (21-30 of 123) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|April 3, 2012
Allogeneic stem cell transplantation for myelofibrosis in 2012Donal P McLornan, Adam J Mead, Graham Jackson, et al.
The New England Journal of Medicine|March 9, 2012
Germline JAK2 mutation in a family with hereditary thrombocytosisAdam J Mead, Michelle J Rugless, Sten Eirik W Jacobsen, et al.
Future Oncology (London, England)|October 1, 2024
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summaryClaire N Harrison, Sonia Fox, Rebecca Boucher, et al.
British Journal of Haematology|February 21, 2020
A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UKClaire N Harrison, Adam J Mead, Mark W Drummond, et al.
STAR Protocols|April 8, 2022
Processing single-cell RNA-seq datasets using SingCellaRGuanlin Wang, Wei Xiong Wen, Adam J Mead, et al.
British Journal of Haematology|August 19, 2021
The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disordersNicholas C P Cross, Anna L Godfrey, Catherine Cargo, et al.
British Journal of Haematology|March 18, 2008
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplicationAdam J Mead, Rosemary E Gale, Panagiotis D Kottaridis, et al.
Leukemia|December 20, 2023
Backtracking to the future: unraveling the origins of childhood leukemiaAdam J de Smith, Joseph L Wiemels, Adam J Mead, et al.
Blood|April 26, 2007
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemiaAdam J Mead, David C Linch, Robert K Hills, et al.
Blood|October 25, 2007
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemiaRosemary E Gale, Claire Green, Christopher Allen, et al.
Pageof 13

Showing results (21-30 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|April 3, 2012
Allogeneic stem cell transplantation for myelofibrosis in 2012Donal P McLornan, Adam J Mead, Graham Jackson, et al.
The New England Journal of Medicine|March 9, 2012
Germline JAK2 mutation in a family with hereditary thrombocytosisAdam J Mead, Michelle J Rugless, Sten Eirik W Jacobsen, et al.
Future Oncology (London, England)|October 1, 2024
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summaryClaire N Harrison, Sonia Fox, Rebecca Boucher, et al.
British Journal of Haematology|February 21, 2020
A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UKClaire N Harrison, Adam J Mead, Mark W Drummond, et al.
STAR Protocols|April 8, 2022
Processing single-cell RNA-seq datasets using SingCellaRGuanlin Wang, Wei Xiong Wen, Adam J Mead, et al.
British Journal of Haematology|August 19, 2021
The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disordersNicholas C P Cross, Anna L Godfrey, Catherine Cargo, et al.
British Journal of Haematology|March 18, 2008
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplicationAdam J Mead, Rosemary E Gale, Panagiotis D Kottaridis, et al.
Leukemia|December 20, 2023
Backtracking to the future: unraveling the origins of childhood leukemiaAdam J de Smith, Joseph L Wiemels, Adam J Mead, et al.
Blood|April 26, 2007
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemiaAdam J Mead, David C Linch, Robert K Hills, et al.
Blood|October 25, 2007
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemiaRosemary E Gale, Claire Green, Christopher Allen, et al.
Pageof 13